Ticker:
MYGN
Primary Sector:
Healthcare
Current Stock Price:
$34.32
High/Base/Low Price Projection:
$49/$23/$8
Morgan Stanley's take: "Myriad is now transitioning to a more comprehensive 25 gene panel, myRisk, which tests for hereditary risk of various cancers. Discussions with insurance payors suggest myRisk is meeting resistance for coverage as payors worry about the lack of data proving clinical utility for broad genomic testing and costs."